Navigation Links
Baxter and Halozyme Announce Collaboration for Development of Subcutaneous GAMMAGARD LIQUID(TM) Administration Using Enhanze(TM) Technology
Date:9/10/2007

ould impact commercialization; and other risks discussed in each company's filings with the Securities and Exchange Commission (SEC) that could cause actual results to differ materially from those in the forward-looking statements. Each company's SEC filings are available on its respective website. The companies do not undertake any obligation to update any forward-looking statements as a result of new information, future events, changes assumptions or otherwise, and all forward- looking statements speak only as of the time when made. Actual results or experience could differ materially from the expectations contained in the forward-looking statements.

HYLENEX recombinant, GAMMAGARD LIQUID and KIOVIG are trademarks of Baxter Healthcare Corporation.

Cumulase and Enhanze are trademarks of Halozyme Therapeutics, Inc.


'/>"/>
SOURCE Baxter International Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Speaker announces business members of IT Task Force
2. Doyle announces technology tax credits for Berbee
3. Doyle announces new energy, global warming policies
4. Doyle, WARF announce partnership to lure stem cell companies
5. Doyle announces $80M renewable energy strategy
6. GE announces first installation of Discovery VCT
7. UWM announces winners of RGI awards
8. Third Wave announces two senior management appointments
9. Mirus announces new method for making antibodies
10. Merge announces sofware updates, upcoming acquisition
11. Small Tree announces ethernet solution for Apple Xserv G5

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/3/2009)... , DALLAS, Dec. 3 /PRNewswire-FirstCall/...in Board: ACCP), today provided an update on its E...ed treatment for oral mucositis, a debilitating si... MuGard is commercially launched by Access, partne...the UK, Germany, Italy, Norway, Greece and Sweden....
(Date:12/3/2009)... , TUSTIN, Calif., Dec. 3 /PRNewswire-Firs... PPHM ) today announced that it will release its ... year 2010 on December 10, 2009 at 7:00 a.m. EST a...uss the results at 11:30 a.m. EST on the same day....financial results for the second quarter ended Oct...
(Date:12/3/2009)... , NEW DELHI, India, Dec. 3 /PRNew... Science Officer at Shenzhen Beike Biotechnology C... a conference on High-Risk Diabetic,Foot Care in N...,s leading,stem cell research and regenerative med...d by the Indian Podiatry Association (IPA), aimed,...
(Date:12/2/2009)... , NEW YORK, Dec. 2 Repo...report is available in its catalogue: ,, Neuro...http://www.reportlinker.com/p0164232/Neurostimulat... world neurostimulation market stands enthused by ...ltant rise in age-related diseases such as, Parkin...
Breaking Biology Technology:Access Pharmaceuticals Provides Update on MuGard Commercial Launch in Europe 2Access Pharmaceuticals Provides Update on MuGard Commercial Launch in Europe 3Access Pharmaceuticals Provides Update on MuGard Commercial Launch in Europe 4Peregrine Pharmaceuticals to Report Second Quarter FY 2010 Financial Results 2Beike Biotechnology CSO Speaks on Role of Stem Cells in Treating Diabetic Foot Disease at IPA Diabetic Foot Care Conference, India 2Beike Biotechnology CSO Speaks on Role of Stem Cells in Treating Diabetic Foot Disease at IPA Diabetic Foot Care Conference, India 3Reportlinker Adds Neurostimulation - A Global Market Perspective 2Reportlinker Adds Neurostimulation - A Global Market Perspective 3Reportlinker Adds Neurostimulation - A Global Market Perspective 4Reportlinker Adds Neurostimulation - A Global Market Perspective 5Reportlinker Adds Neurostimulation - A Global Market Perspective 6
...Genaera,Corporation (Nasdaq: GENR ) today announc...ch 31, 2008. The net loss for the quarter ended Ma... and diluted share, as compared,to a net loss of $...e, for,the quarter ended March 31, 2007., Genaera...er ended March,31, 2008 were $3.8 million compared...
...st - Toronto Stock Exchange Symb...BioMS Medical Corp (TSX: MS),a leading developer i...announced an update on its pipeline products, HYC7...y has entered into a Royalty and Assignment Agreem...y based on hyaluronic acid that,has a number of po...
...lexander von Humboldt,Foundation, one of the world...ed that it has named Dr. Robert Knight as a winner... for 2008 in the area of neurobiology.,It is the o...gory., Headquartered in Bonn, Germany, the Humbol...nal candidates each year for its awards program.,N...
Other Biology Technology:Genaera Corporation Announces First Quarter Financial Results 2Genaera Corporation Announces First Quarter Financial Results 3Genaera Corporation Announces First Quarter Financial Results 4BioMS Medical Provides Update On Pipeline Products 2BioMS Medical Provides Update On Pipeline Products 3NeuroFocus Chief Science Advisor Wins Humboldt Prize 2
(Date:12/3/2009)... change in warmer water, according to an intriguin...e some species more aggressive. , Experiments wi...Great Barrier Reef have shown for the first time t...or consistently bold, and that these individual di...es rise. , A slight lift of just one or two degr...
(Date:12/3/2009)...esign of the upcoming forest deal at Copenhagen in...o a scientist at the University of Leeds. , Wri... at least 50% of the carbon credit payments to be ...sions from Deforestation and Degredation), should ...perty rights assured. , "There is the potential ...
(Date:12/3/2009)...nvestment in energy efficient technologies researc...Council (EPSRC) Chief Executive Dave Delpy believe... research has already brought us fuel cells, marin...ment is needed to develop the capabilities of diff...ion targets by 2020 and limit the impact of climat...
Breaking Biology News(10 mins):Fish with attitude: Some like it hot 2Forest deal at Copenhagen must avoid creating 'carbon refugees' 2Research is vital to a cleaner, greener, low carbon future 2MRI accurately depicts deep endometriosis 50842 1MRI accurately depicts deep endometriosis 50842 2News briefs from the July issue of CHEST 50840 1News briefs from the July issue of CHEST 50840 2Expert Explains Why Propofol Was the Wrong and Possibly Fatal Drug for Michael Jackson 50839 1Expert Explains Why Propofol Was the Wrong and Possibly Fatal Drug for Michael Jackson 50839 2
...ough the lens of the microscope at tiny sections o...nnual bands of growth. She carefully counts the ba...n to the next sample. Known as an age reader, Sut...Fisheries Science Center (NEFSC) whose aging work ...the nations fishery resources in the Northwest Atl...
.... , , Bonn/Berlin. What will the loss of biodiver...l economies need to invest now in order to stop th...do not act" These are the questions the TEEB -- Th...ct is seeking to answer. The pilot study led by Pa... Market Centre in London, was commissioned by the ...
...s that control electrical excitability in a portio...ke insomnia disorder in mice, UT Southwestern Medi...y help scientists better understand the disorder a...ts. , This is one of the most dramatic sleep-dis...professor of neuroscience and senior author of the...
Other Biology News:Saltwater sleuths: Seeking clues to help determine the ages of fish and shellfish populations 2Saltwater sleuths: Seeking clues to help determine the ages of fish and shellfish populations 3Saltwater sleuths: Seeking clues to help determine the ages of fish and shellfish populations 4Biodiversity as a natural resource 2Gene mutations in mice mimic human-like sleep disorder, UT Southwestern researchers find 2
RNA Sample Buffer from Novagen
Eppendorf capping aid from Sigma-Aldrich
...d, the Quansys Biosciences Q-Plex Array is a new t...okines for human, mouse, and rat research. The Q-P...SA-based test where 4 distinct capture antibodies ... in a defined array. Analytes measured are IL-2, ...
Strip Cap Tool from Bio-Rad
Biology Products: